SBC SBC Medical Group Holdings Inc
FY2024 10-K
SBC Medical Group Holdings Inc (SBC) filed its fiscal year 2024 10-K annual report with the SEC on Mar 28, 2025. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2024 10-K
Business Overview
- • Core business: Medical aesthetics franchising, procurement, management, and rental services focusing on clinic networks in Japan
- • New emphasis on franchising revenue model change in 2024: fixed royalty fees per clinic replacing percentage of sales, authorized MCs to use patents/trademarks
Management Discussion & Analysis
- • No revenue or profit figures disclosed; focus on internal control weaknesses and remediation efforts
- • Identified material weaknesses in internal controls including control environment, activities, risk assessment, communication, monitoring
Risk Factors
- • Regulatory risk from Japanese Medical Care Act limiting voting control over Medical Corporations despite equity interests
- • Geopolitical exposure in Japan with all 241 treatment centers operated under six related-party Medical Corporations
Financial SummaryXBRL
Revenue
$205M
Net Income
$47M
Gross Margin
76.0%
Operating Margin
34.2%
Net Margin
22.7%
ROE
23.9%
Total Assets
$266M
EPS (Diluted)
$0.48
Operating Cash Flow
$21M
Source: XBRL data from SBC Medical Group Holdings Inc FY2024 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on SBC Medical Group Holdings Inc
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.